Andrew Harmon, plenary speaker, will present regulatory insights at the Indiana CTSI’s 2026 Annual Meeting on genetic medicine

How can we turn discoveries into treatments that will improve people’s lives—and faster?

If you are attending the Indiana CTSI’s 2026 Annual Meeting this year, you will get the chance to hear a leader in gene therapy at the U.S. Food & Drug Administration (FDA) answer this question.

Andrew Harmon, PhD, is chief of Gene Therapy Branch 1 in the FDA’s Office of Therapeutic Products at the Center for Biologics Evaluation and Research. At the meeting on September 18 in Indianapolis, he will deliver the plenary address, “Accelerating Development of Genetic Therapies for Rare Diseases.”

This discussion will serve as an excellent capstone to the rest of the event’s robust presentations about innovations in genetic medicine.

“Gene therapy holds transformative potential for patients living with rare diseases,” Harmon said. “I am excited to share how recently published guidance documents can give sponsors practical tools to accelerate development of the next generation of genetic therapies.”

There is still time to register to attend the meeting. Register today, and you can also learn more about Harmon on our speaker information page.